niche

Depo-Provera MRI Screening

Preparing your case review…
Written By
People's Justice Legal Research Team

Should I Get an MRI If I Used Depo-Provera?

Current clinical guidelines do NOT recommend routine MRI screening for all Depo-Provera users who are feeling well. However, the December 2025 FDA label update instructs providers to "monitor patients on Depo-Provera CI for signs and symptoms of meningioma." This means your doctor should be asking about headaches, vision changes, and neurological symptoms at every visit.

When MRI Screening IS Recommended

Researchers recommend neurological monitoring (including imaging) for women who used Depo-Provera for more than 10 years, patients over 40 years of age with prolonged use, any woman experiencing new headaches, vision changes, seizures, or other neurological symptoms, and women with a family history of meningioma. If you fall into any of these categories, discuss MRI screening with your doctor.

The MRI Process

Contrast-enhanced MRI of the brain is the gold standard for meningioma detection. The scan takes 30–60 minutes and uses gadolinium contrast dye to highlight tumors. If a meningioma is found, additional imaging may include MRI spectroscopy, CT angiography, or PET scanning to characterize the tumor. The MRI result is also critical evidence for your legal claim.

Cost and Insurance Coverage

Brain MRI costs $1,000–$5,000 without insurance. Most insurance plans cover MRI when ordered by a physician for diagnostic purposes (i.e., you have symptoms). If your doctor orders an MRI based on Depo-Provera use history and you are experiencing symptoms, the test should be covered. Keep all billing records — imaging costs are recoverable in your lawsuit.

Research & Evidence

Scientific Evidence

Medroxyprogesterone Acetate and Meningioma: A Global Issue

Roland N, Froelich S, Weill A (2025). Frontiers in Global Womens Health

View on PubMed

Use of High-Dose Medroxyprogesterone Acetate and Risk of Intracranial Meningioma

Roland N, Neumann A, Hoisnard L, Gagne JJ, Froelich S, Weill A (2024). The BMJ

View on PubMed

The Association between Medroxyprogesterone Acetate Exposure and Meningioma

Griffin BR et al. (2024). Cancers

View on PubMed
FAQ

Frequently Asked Questions

See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
Related Topics

Related Pages

Depo-Provera Meningioma Brain Tumor

Meningioma — a tumor in the tissue surrounding the brain — is the primary injury in Depo-Provera lawsuits. Studies show long-term users face up to a 5.6x increased risk. The tumor can cause seizures, vision loss, and require major brain surgery.

meningiomabrain-tumorprogesterone-receptor
Learn more

Depo-Provera Brain Tumor Symptoms

Meningioma symptoms develop gradually and include persistent headaches, vision changes, seizures, and cognitive decline. If you used Depo-Provera and experience these symptoms, request brain imaging from your doctor.

symptomsheadacheseizure
Learn more

Depo-Provera Long-Term Use Risks

Long-term Depo-Provera use carries multiple serious risks: meningioma brain tumors (up to 5.6x risk), significant bone density loss (black box warning), weight gain, depression, and delayed return to fertility. The FDA recommends limiting use to 2 years.

long-term-usebone-densitycumulative-risk
Learn more

Depo-Provera Settlement Amounts

No Depo-Provera meningioma cases have settled or gone to trial yet. Projected settlements based on comparable pharmaceutical brain injury litigation suggest $75,000 to $1.5 million+ depending on injury severity.

settlement-amountsprojected-valuesmdl-3140
Learn more

Pfizer Depo-Provera Lawsuit

Pfizer inherited Depo-Provera when it acquired Pharmacia & Upjohn in 2002. Despite international warnings dating to 2015, Pfizer did not add a U.S. meningioma warning until December 2025. Plaintiffs allege a pattern of delayed safety action prioritizing revenue over patient safety.

pfizerpharmaciaupjohn
Learn more

Depo-Provera Alternatives After Diagnosis

If you are diagnosed with a meningioma, the FDA recommends discontinuing Depo-Provera immediately. Safer contraceptive alternatives exist that do not carry meningioma risk, including copper IUDs, barrier methods, and non-progestin options.

alternativescontraceptioncopper-iud
Learn more

Depo-Provera Military Veterans

Military women were disproportionately prescribed Depo-Provera due to its convenience for deployment. If you received Depo-Provera during military service and were later diagnosed with a meningioma, you may be eligible for both civil lawsuit compensation and VA benefits.

militaryveteransdeployment
Learn more
Parent Case

Depo-Provera Brain Tumor Lawsuits Lawsuit

Depo-Provera (medroxyprogesterone acetate / MPA) is a contraceptive injection administered every three months. Over 2,000 lawsuits consolidated in MDL 3140 in the Northern District of Florida allege that Pfizer failed to warn about a significantly elevated risk of meningioma — a tumor in the tissue surrounding the brain and spinal cord. Women who received the shot for more than one year face up to a 5.6-fold increased risk, and the risk escalates with duration of use.

View full case overview